Novavax Pins COVID-19 Hopes On Ex-US, Booster Markets
Delay In FDA Filing Until Q4
The company is planning to file with regulators in the UK, EU, Canada, Australia and New Zealand, with an emphasis on booster shots in developed markets.
You may also be interested in...
The FDA authorized Comirnaty as a booster shot for 12- to 15-year-olds, as J&J's vaccine has shown effectiveness as a booster in Omicron-dominant settings. Meanwhile, Pfizer's Paxlovid won approval in the UK, and Novavax submitted the final data for its vaccine to the FDA.
Novavax’s Lisa Dunkle talked to Scrip about the time and effort that went into building trust among Native American communities to encourage participation in its COVID-19 vaccine study.
A US FDA review panel has given a lukewarm reception to molnupiravir, while Inovio is assessing its vaccine candidates against the new omicron variant, J&J nears a South African vaccine deal with Aspen, and South Korea brings in new COVID-19 measures. Meanwhile, Serum exports Novavax vaccine, Bharat looks at Covaxin in Omicron and Ocugen's Covaxin trial put on hold.